Early response to ranibizumab predictive of functional outcome after dexamethasone for unresponsive diabetic macular oedema

British Journal of Ophthalmology

Volumn 101, Issue 12, 2017, Pages 1689-1693

  Cicinelli, Maria Vittoria ^a   Cavalleri, Michele ^a   Querques, Lea ^a   Rabiolo, Alessandro ^a   Bandello, Francesco ^a   Querques, Giuseppe ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

anti VEGF; dexamethasone; diabetic macular edema; ranibizumab

Indexed keywords

BEVACIZUMAB; CORTICOSTEROID; DEXAMETHASONE; PEGAPTANIB; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; GLUCOCORTICOID; VASCULOTROPIN A;

AGED; ARTICLE; BEST CORRECTED VISUAL ACUITY; CENTRAL MACULAR THICKNESS; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; DIABETIC MACULAR EDEMA; DISEASE ASSOCIATION; DRUG EFFECT; DRUG IMPLANTATION; DRUG RESPONSE; FEMALE; FOLLOW UP; HUMAN; LOADING DRUG DOSE; LONG TERM CARE; MALE; MORPHOLOGY; PREDICTIVE VALUE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SHORT COURSE THERAPY; TREATMENT OUTCOME; VISION; ANTAGONISTS AND INHIBITORS; COMPLICATION; DIABETIC RETINOPATHY; DOSE RESPONSE; DRUG IMPLANT; DRUG SUBSTITUTION; INTRAVITREAL DRUG ADMINISTRATION; MACULAR EDEMA; OPTICAL COHERENCE TOMOGRAPHY; PATHOLOGY; RETINA MACULA LUTEA; TIME FACTOR; VISUAL ACUITY;

AGED; ANGIOGENESIS INHIBITORS; DEXAMETHASONE; DIABETIC RETINOPATHY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG IMPLANTS; DRUG SUBSTITUTION; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; INTRAVITREAL INJECTIONS; MACULA LUTEA; MACULAR EDEMA; MALE; RANIBIZUMAB; RETROSPECTIVE STUDIES; TIME FACTORS; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 85037680578     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjophthalmol-2017-310242     Document Type: Article

References (21)

1. Kempen JH, O Colmain BJ, Leske MC, et al. Eye diseases prevalence research group the prevalence of diabetic retinopathy among adults in the united states. Arch Ophthalmol 2004; 122: 552-63
2. Bandello F, Battaglia Parodi M, Lanzetta P, et al. Diabetic macular edema. Dev Ophthalmol 2010; 47: 73-110
3. Early treatment diabetic retinopathy study research group. Photocoagulation for diabetic macular edema. early treatment diabetic retinopathy study report number 1. Arch Ophthalmol 1985; 103: 1796-806
4. Iacono P, Battaglia Parodi M, Bandello F. Antivascular endothelial growth factor in diabetic retinopathy. Dev Ophthalmol 2010; 46: 39-53
5. Bandello F, Berchicci L, La Spina C, et al. Evidence for anti-VEGF treatment of diabetic macular edema. Ophthalmic Res 2012; 48 Suppl 1: 16-20
6. Gonzalez VH, Campbell J, Holekamp NM, et al. Early and Long-Term responses to Anti-Vascular endothelial growth factor therapy in diabetic macular edema: analysis of protocol I data. Am J Ophthalmol 2016; 172: 72-9
7. Bandello F, Cunha-Vaz J, Chong NV, et al. New approaches for the treatment of diabetic macular oedema: recommendations by an expert panel. Eye 2012; 26: 485-93
8. Bandello F, Battaglia Parodi M, Tremolada G, et al. Steroids as part of combination treatment: the future for the management of macular edema? Ophthalmologica 2010; 224 Suppl 1: 41-5
9. Murakami T, Yoshimura N. Structural changes in individual retinal layers in diabetic macular edema. J Diabetes Res 2013; 2013: 1-11
10. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. early treatment diabetic retinopathy study research group. Ophthalmology 1991; 98: 766-85
11. Nguyen QD, Brown DM, Marcus DM, et al; RISE and RIDE Research Group. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: rise and RIDE. Ophthalmology 2012; 119: 789-801
12. Brown DM, Nguyen QD, Marcus DM, et al; RIDE and RISE Research Group. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology 2013; 120: 2013-22
13. Kuppermann BD, Blumenkranz MS, Haller JA, et al; Dexamethasone DDS Phase II Study Group. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol 2007; 125: 309-17
14. Haller JA, Kuppermann BD, Blumenkranz MS, et al; Dexamethasone DDS Phase II Study Group. Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. Arch Ophthalmol 2010; 128: 289-96
15. Querques G, Darvizeh F, Querques L, et al. Assessment of the Real-Life usage of intravitreal dexamethasone implant in the treatment of chronic diabetic macular edema in France. J Ocul Pharmacol Ther 2016; 32: 383-9
16. Scaramuzzi M, Querques G, Spina CL, et al. Repeated intravitreal dexamethasone implant (Ozurdex) for diabetic macular edema. Retina 2015; 35: 1216-22
17. Zucchiatti I, Lattanzio R, Querques G, et al. Intravitreal dexamethasone implant in patients with persistent diabetic macular edema. Ophthalmologica 2012; 228: 117-22
18. Antonetti DA, Wolpert EB, DeMaio L, et al. Hydrocortisone decreases retinal endothelial cell water and solute flux coincident with increased content and decreased phosphorylation of occludin. J Neurochem 2002; 80: 667-77
19. Silva PS, Sun JK, Aiello LP. Role of steroids in the management of diabetic macular edema and proliferative diabetic retinopathy. Semin Ophthalmol 2009; 24: 93-9
20. Bhisitkul RB, Winn BJ, Lee OT, et al. Neuroprotective effect of intravitreal triamcinolone acetonide against photoreceptor apoptosis in a rabbit model of subretinal hemorrhage. Invest Ophthalmol Vis Sci 2008; 49: 4071-7
21. Wang L, Zhang Z, McArdle JJ, et al. Investigating ceiling effects in longitudinal data analysis. Multivariate Behav Res 2009; 43: 476-96